ABOUT US
CONTACT US
FAQ
PRIVACY POLICY
REFUND AND CANCELLATION
BLOGS
COMPANIES
REPORTS
0
U.S. (TOLL FREE)
+1 (315) 215-3225
Automative
0
U.S. (TOLL FREE)
+1 (315) 215-3225
Global Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size, Manufacturers, Supply Chain, Sales Channel and Clients, 2025-2031
Published Date: July 2025
|
Report Code: QYRE-Auto-17W2541
Home | Market Reports | Health| Health Conditions| Neurological Conditions
China Amyotrophic Lateral Sclerosis ALS Treatment Market Report Forecast 2021 2027
BUY CHAPTERS

Global Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size, Manufacturers, Supply Chain, Sales Channel and Clients, 2025-2031

Code: QYRE-Auto-17W2541
Report
July 2025
Pages:118
QYResearch
Buy Now with 15% Discount
DESCRIPTION
TABLE OF CONTENT
TABLES & FIGURES
FEATURED COMPANIES
Mitsubishi Tanabe Pharma
Sanofi
Mylan Pharma
Apotex
Glemark Generics
Covis Pharma
Sun Pharma
Lunan Pharma

Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size

Treatment was estimated to be worth US$ 350 million and is forecast to reach approximately US$ 599 million by 2031 with a CAGR of 8.1% during the forecast period 2025-2031.

Amyotrophic Lateral Sclerosis (ALS) Treatment Market

Amyotrophic Lateral Sclerosis (ALS) Treatment Market

In 2024, the global market size of Amyotrophic Lateral Sclerosis (ALS)
Amyotrophic lateral sclerosis (ALS) is also known as Lou Gehrig’s disease or Maladie De Charcot, it is a neurological disease that causes nerve cells to gradually break down and die.
The cause is not known in 90% to 95% of cases. The remaining 5–10% of cases are inherited from a person"s parents. About half of these genetic cases are due to one of two specific genes. The underlying mechanism involves damage to both upper and lower motor neurons. The diagnosis is based on a person"s signs and symptoms, with testing done to rule out other potential causes.
GlobalAmyotrophic Lateral Sclerosis (ALS) Treatment key players include Mitsubishi Tanabe Pharma, Sanofi, etc. Global top two manufacturers hold a share over 80%.
North America is the largest market, with a share about 60%, followed by Japan, and Europe, both have a share over 20 percent.
In terms of product, Edaravone (Radicava) is the largest segment, with a share over 75%. And in terms of application, the largest application is Hospital, followed by Drugs Store, etc.

Report Scope

This report aims to provide a comprehensive presentation of the global market for Amyotrophic Lateral Sclerosis (ALS) Treatment, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Amyotrophic Lateral Sclerosis (ALS) Treatment.
The Amyotrophic Lateral Sclerosis (ALS) Treatment market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Amyotrophic Lateral Sclerosis (ALS) Treatment market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Amyotrophic Lateral Sclerosis (ALS) Treatment companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, product type, application, and regions.
Market Segmentation

Scope of Amyotrophic Lateral Sclerosis (ALS) Treatment Market Report

Report Metric Details
Report Name Amyotrophic Lateral Sclerosis (ALS) Treatment Market
Forecasted market size in 2031 approximately US$ 599 million
CAGR 8.1%
Forecasted years 2025 - 2031
Segment by Type
  • Riluzole
  • Edaravone (Radicava)
  • Other
Segment by Application
  • Hospital
  • Drugs Store
  • Other
By Region
  • North America (United States, Canada)
  • Europe (Germany, France, UK, Italy, Russia) Rest of Europe
  • Nordic Countries
  • Asia-Pacific (China, Japan, South Korea)
  • Southeast Asia (India, Australia)
  • Rest of Asia
  • Latin America (Mexico, Brazil)
  • Rest of Latin America
  • Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of MEA)
By Company Mitsubishi Tanabe Pharma, Sanofi, Mylan Pharma, Apotex, Glemark Generics, Covis Pharma, Sun Pharma, Lunan Pharma
Forecast units USD million in value
Report coverage Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Chapter Outline

  • Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on.
  • Chapter 2: Revenue of Amyotrophic Lateral Sclerosis (ALS) Treatment in global and regional level.
  • Chapter 3: Detailed analysis of Amyotrophic Lateral Sclerosis (ALS) Treatment company competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
  • Chapter 4: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Amyotrophic Lateral Sclerosis (ALS) Treatment revenue, gross margin, and recent development, etc.
  • Chapter 5: Provides the analysis of various market segments by Type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
  • Chapter 6: Provides the analysis of various market segments by Application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
  • Chapter 7: North America (US & Canada) by Type, by Application and by country, revenue for each segment.
  • Chapter 8: Europe by Type, by Application and by country, revenue for each segment.
  • Chapter 9: Asia Pacific by Type, by Application and by region, revenue for each segment.
  • Chapter 10: Latin America by Type, by Application and by country, revenue for each segment.
  • Chapter 11: Middle East and Africa, by Type, by Application and by country, revenue for each segment.
  • Chapter 12: Analysis of industrial chain, sales channel, key raw materials, distributors, and customers.
  • Chapter 13: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
  • Chapter 14: Research Findings and Conclusion

FAQ for this report

What is the Amyotrophic Lateral Sclerosis (ALS) Treatment Market size in 2031?

Ans: The Amyotrophic Lateral Sclerosis (ALS) Treatment Market size in 2031 will be approximately US$ 599 million.

What is the market share of major companies in Amyotrophic Lateral Sclerosis (ALS) Treatment Market?

Ans: Global top two manufacturers hold a share over 80%.

What is the Amyotrophic Lateral Sclerosis (ALS) Treatment Market share by type?

Ans: In terms of product, Edaravone (Radicava) is the largest segment, with a share over 75%.

Who are the main players in the Amyotrophic Lateral Sclerosis (ALS) Treatment Market report?

Ans: The main players in the Amyotrophic Lateral Sclerosis (ALS) Treatment Market are Mitsubishi Tanabe Pharma, Sanofi, Mylan Pharma, Apotex, Glemark Generics, Covis Pharma, Sun Pharma, Lunan Pharma

What are the Application segmentation covered in the Amyotrophic Lateral Sclerosis (ALS) Treatment Market report?

Ans: The Applications covered in the Amyotrophic Lateral Sclerosis (ALS) Treatment Market report are Hospital, Drugs Store, Other

What are the Type segmentation covered in the Amyotrophic Lateral Sclerosis (ALS) Treatment Market report?

Ans: The Types covered in the Amyotrophic Lateral Sclerosis (ALS) Treatment Market report are Riluzole, Edaravone (Radicava), Other

1 Study Coverage
1.1 Amyotrophic Lateral Sclerosis (ALS) Treatment Product Introduction
1.2 Market by Type
1.2.1 Global Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size Growth Rate by Type (2020 VS 2024 VS 2031)
1.2.2 Riluzole
1.2.3 Edaravone (Radicava)
1.2.4 Other
1.3 Market by Application
1.3.1 Global Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size Growth Rate by Application (2020 VS 2024 VS 2031)
1.3.2 Hospital
1.3.3 Drugs Store
1.3.4 Other
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Executive Summary
2.1 Global Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size Estimates and Forecasts
2.2 Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size by Region: 2024 Versus 2031
2.2.1 Global Amyotrophic Lateral Sclerosis (ALS) Treatment Revenue by Region: 2020-2025
2.2.2 Global Amyotrophic Lateral Sclerosis (ALS) Treatment Revenue Forecast by Region (2026-2031)
2.2.3 Global Amyotrophic Lateral Sclerosis (ALS) Treatment Revenue Market Share by Region (2020-2031)
3 Market Segments
3.1 Breakdown Data by Type
3.1.1 Global Amyotrophic Lateral Sclerosis (ALS) Treatment Revenue by Type (2020-2031)
3.1.2 Global Amyotrophic Lateral Sclerosis (ALS) Treatment Revenue Market Share by Type (2020-2031)
3.2 Breakdown Data by Application
3.2.1 Global Amyotrophic Lateral Sclerosis (ALS) Treatment Revenue by Application (2020-2031)
3.2.2 Global Amyotrophic Lateral Sclerosis (ALS) Treatment Revenue Market Share by Application (2020-2031)
3.3 by Type and by Application Crossing Analysis
3.3.1 Riluzole of Amyotrophic Lateral Sclerosis (ALS) Treatment Revenue Market Share by Application
3.3.2 Edaravone (Radicava) of Amyotrophic Lateral Sclerosis (ALS) Treatment Revenue Market Share by Application
3.3.3 Other of Amyotrophic Lateral Sclerosis (ALS) Treatment Revenue Market Share by Application
4 Global Amyotrophic Lateral Sclerosis (ALS) Treatment by Company
4.1 Global Amyotrophic Lateral Sclerosis (ALS) Treatment Revenue by Company (2020-2025)
4.2 Global Amyotrophic Lateral Sclerosis (ALS) Treatment Revenue Share by Company (2020-2025)
4.3 Competitive Landscape
4.3.1 Key Amyotrophic Lateral Sclerosis (ALS) Treatment Companies around the World: Ranking by Revenue
4.3.2 Global Amyotrophic Lateral Sclerosis (ALS) Treatment Market Concentration Ratio (CR5 and HHI) & (2020-2025)
4.3.3 Global Amyotrophic Lateral Sclerosis (ALS) Treatment Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
4.4 Global Amyotrophic Lateral Sclerosis (ALS) Treatment Companies Headquarters & Product Type
4.4.1 Global Amyotrophic Lateral Sclerosis (ALS) Treatment Companies Headquarters
4.4.2 Date of International Companies Enter into Amyotrophic Lateral Sclerosis (ALS) Treatment Market
4.4.3 Global Amyotrophic Lateral Sclerosis (ALS) Treatment Companies Product & Service
4.4.4 Riluzole Revenue Market Share of Amyotrophic Lateral Sclerosis (ALS) Treatment by Company
4.4.5 Edaravone (Radicava) Revenue Market Share of Amyotrophic Lateral Sclerosis (ALS) Treatment by Company
4.4.6 Other Revenue Market Share of Amyotrophic Lateral Sclerosis (ALS) Treatment by Company
4.5 Global Amyotrophic Lateral Sclerosis (ALS) Treatment Mergers & Acquisitions, Expansion Plans
5 Company Profiles
5.1 Mitsubishi Tanabe Pharma
5.1.1 Mitsubishi Tanabe Pharma Corporation Information
5.1.2 Mitsubishi Tanabe Pharma Description, Business Overview
5.1.3 Mitsubishi Tanabe Pharma Amyotrophic Lateral Sclerosis (ALS) Treatment Products Offered
5.1.4 Mitsubishi Tanabe Pharma Amyotrophic Lateral Sclerosis (ALS) Treatment Revenue and Gross Margin (2020-2025)
5.1.5 Mitsubishi Tanabe Pharma Amyotrophic Lateral Sclerosis (ALS) Treatment Revenue by Product in 2024
5.1.6 Mitsubishi Tanabe Pharma Amyotrophic Lateral Sclerosis (ALS) Treatment Revenue by Application in 2024
5.1.7 Mitsubishi Tanabe Pharma Amyotrophic Lateral Sclerosis (ALS) Treatment Revenue by Geographic Area in 2024
5.1.8 Mitsubishi Tanabe Pharma Recent Developments
5.2 Sanofi
5.2.1 Sanofi Corporation Information
5.2.2 Sanofi Description, Business Overview
5.2.3 Sanofi Amyotrophic Lateral Sclerosis (ALS) Treatment Products Offered
5.2.4 Sanofi Amyotrophic Lateral Sclerosis (ALS) Treatment Revenue and Gross Margin (2020-2025)
5.2.5 Sanofi Amyotrophic Lateral Sclerosis (ALS) Treatment Revenue by Product in 2024
5.2.6 Sanofi Amyotrophic Lateral Sclerosis (ALS) Treatment Revenue by Application in 2024
5.2.7 Sanofi Amyotrophic Lateral Sclerosis (ALS) Treatment Revenue by Geographic Area in 2024
5.2.8 Sanofi Recent Developments
5.3 Mylan Pharma
5.3.1 Mylan Pharma Corporation Information
5.3.2 Mylan Pharma Description, Business Overview
5.3.3 Mylan Pharma Amyotrophic Lateral Sclerosis (ALS) Treatment Products Offered
5.3.4 Mylan Pharma Amyotrophic Lateral Sclerosis (ALS) Treatment Revenue and Gross Margin (2020-2025)
5.3.5 Mylan Pharma Amyotrophic Lateral Sclerosis (ALS) Treatment Revenue by Product in 2024
5.3.6 Mylan Pharma Amyotrophic Lateral Sclerosis (ALS) Treatment Revenue by Application in 2024
5.3.7 Mylan Pharma Amyotrophic Lateral Sclerosis (ALS) Treatment Revenue by Geographic Area in 2024
5.3.8 Mylan Pharma Recent Developments
5.4 Apotex
5.4.1 Apotex Corporation Information
5.4.2 Apotex Description, Business Overview
5.4.3 Apotex Amyotrophic Lateral Sclerosis (ALS) Treatment Products Offered
5.4.4 Apotex Amyotrophic Lateral Sclerosis (ALS) Treatment Revenue and Gross Margin (2020-2025)
5.4.5 Apotex Amyotrophic Lateral Sclerosis (ALS) Treatment Revenue by Product in 2024
5.4.6 Apotex Amyotrophic Lateral Sclerosis (ALS) Treatment Revenue by Application in 2024
5.4.7 Apotex Amyotrophic Lateral Sclerosis (ALS) Treatment Revenue by Geographic Area in 2024
5.4.8 Apotex Recent Developments
5.5 Glemark Generics
5.5.1 Glemark Generics Corporation Information
5.5.2 Glemark Generics Description, Business Overview
5.5.3 Glemark Generics Amyotrophic Lateral Sclerosis (ALS) Treatment Products Offered
5.5.4 Glemark Generics Amyotrophic Lateral Sclerosis (ALS) Treatment Revenue and Gross Margin (2020-2025)
5.5.5 Glemark Generics Amyotrophic Lateral Sclerosis (ALS) Treatment Revenue by Product in 2024
5.5.6 Glemark Generics Amyotrophic Lateral Sclerosis (ALS) Treatment Revenue by Application in 2024
5.5.7 Glemark Generics Amyotrophic Lateral Sclerosis (ALS) Treatment Revenue by Geographic Area in 2024
5.5.8 Glemark Generics Recent Developments
5.6 Covis Pharma
5.6.1 Covis Pharma Corporation Information
5.6.2 Covis Pharma Description, Business Overview
5.6.3 Covis Pharma Amyotrophic Lateral Sclerosis (ALS) Treatment Products Offered
5.6.4 Covis Pharma Amyotrophic Lateral Sclerosis (ALS) Treatment Revenue and Gross Margin (2020-2025)
5.6.5 Covis Pharma Amyotrophic Lateral Sclerosis (ALS) Treatment Revenue by Product in 2024
5.6.6 Covis Pharma Amyotrophic Lateral Sclerosis (ALS) Treatment Revenue by Application in 2024
5.6.7 Covis Pharma Amyotrophic Lateral Sclerosis (ALS) Treatment Revenue by Geographic Area in 2024
5.6.8 Covis Pharma Recent Developments
5.7 Sun Pharma
5.7.1 Sun Pharma Corporation Information
5.7.2 Sun Pharma Description, Business Overview
5.7.3 Sun Pharma Amyotrophic Lateral Sclerosis (ALS) Treatment Products Offered
5.7.4 Sun Pharma Amyotrophic Lateral Sclerosis (ALS) Treatment Revenue and Gross Margin (2020-2025)
5.7.5 Sun Pharma Amyotrophic Lateral Sclerosis (ALS) Treatment Revenue by Product in 2024
5.7.6 Sun Pharma Amyotrophic Lateral Sclerosis (ALS) Treatment Revenue by Application in 2024
5.7.7 Sun Pharma Amyotrophic Lateral Sclerosis (ALS) Treatment Revenue by Geographic Area in 2024
5.7.8 Sun Pharma Recent Developments
5.8 Lunan Pharma
5.8.1 Lunan Pharma Corporation Information
5.8.2 Lunan Pharma Description, Business Overview
5.8.3 Lunan Pharma Amyotrophic Lateral Sclerosis (ALS) Treatment Products Offered
5.8.4 Lunan Pharma Amyotrophic Lateral Sclerosis (ALS) Treatment Revenue and Gross Margin (2020-2025)
5.8.5 Lunan Pharma Amyotrophic Lateral Sclerosis (ALS) Treatment Revenue by Product in 2024
5.8.6 Lunan Pharma Amyotrophic Lateral Sclerosis (ALS) Treatment Revenue by Application in 2024
5.8.7 Lunan Pharma Amyotrophic Lateral Sclerosis (ALS) Treatment Revenue by Geographic Area in 2024
5.8.8 Lunan Pharma Recent Developments
6 North America
6.1 North America Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size YoY Growth 2020-2031
6.2 North America Amyotrophic Lateral Sclerosis (ALS) Treatment Market Facts & Figures by Country (2020-2031)
6.3 North America Amyotrophic Lateral Sclerosis (ALS) Treatment Revenue by Type (2020-2025)
6.4 North America Amyotrophic Lateral Sclerosis (ALS) Treatment Revenue by Application (2020-2025)
7 Asia-Pacific
7.1 Asia-Pacific Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size YoY Growth 2020-2031
7.2 Asia-Pacific Amyotrophic Lateral Sclerosis (ALS) Treatment Market Facts & Figures by Region (2020-2031)
7.3 Asia-Pacific Amyotrophic Lateral Sclerosis (ALS) Treatment Revenue by Type (2020-2025)
7.4 Asia-Pacific Amyotrophic Lateral Sclerosis (ALS) Treatment Revenue by Application (2020-2025)
8 Europe
8.1 Europe Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size YoY Growth 2020-2031
8.2 Europe Amyotrophic Lateral Sclerosis (ALS) Treatment Market Facts & Figures by Country (2020-2031)
8.3 Europe Amyotrophic Lateral Sclerosis (ALS) Treatment Revenue by Type (2020-2025)
8.4 Europe Amyotrophic Lateral Sclerosis (ALS) Treatment Revenue by Application (2020-2025)
9 Latin America
9.1 Latin America Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size YoY Growth 2020-2031
9.2 Latin America Amyotrophic Lateral Sclerosis (ALS) Treatment Market Facts & Figures by Country (2020-2031)
9.3 Latin America Amyotrophic Lateral Sclerosis (ALS) Treatment Revenue by Type (2020-2025)
9.4 Latin America Amyotrophic Lateral Sclerosis (ALS) Treatment Revenue by Application (2020-2025)
10 Middle East and Africa
10.1 Latin America Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size YoY Growth 2020-2031
10.2 Middle East and Africa Amyotrophic Lateral Sclerosis (ALS) Treatment Market Facts & Figures by Country (2020-2031)
10.3 Middle East and Africa Amyotrophic Lateral Sclerosis (ALS) Treatment Revenue by Type (2020-2025)
10.4 Middle East and Africa Amyotrophic Lateral Sclerosis (ALS) Treatment Revenue by Application (2020-2025)
11 Supply Chain and Sales Channel analysis
11.1 Amyotrophic Lateral Sclerosis (ALS) Treatment Supply Chain Analysis
11.2 Amyotrophic Lateral Sclerosis (ALS) Treatment Key Raw Materials and Upstream Suppliers
11.3 Amyotrophic Lateral Sclerosis (ALS) Treatment Clients Analysis
11.4 Amyotrophic Lateral Sclerosis (ALS) Treatment Sales Channel and Sales Model Analysis
11.4.1 Amyotrophic Lateral Sclerosis (ALS) Treatment Distribution Channel Analysis: Indirect Sales VS Direct Sales
11.4.2 Amyotrophic Lateral Sclerosis (ALS) Treatment Distribution Channel Analysis: Online Sales VS Offline Sales
11.4.3 Amyotrophic Lateral Sclerosis (ALS) Treatment Distributors
12 Amyotrophic Lateral Sclerosis (ALS) Treatment Market Dynamics
12.1 Amyotrophic Lateral Sclerosis (ALS) Treatment Industry Trends
12.2 Amyotrophic Lateral Sclerosis (ALS) Treatment Market Drivers
12.3 Amyotrophic Lateral Sclerosis (ALS) Treatment Market Challenges
12.4 Amyotrophic Lateral Sclerosis (ALS) Treatment Market Restraints
13 Research Findings and Conclusion
14 Appendix
14.1 Research Methodology
14.1.1 Methodology/Research Approach
14.1.1.1 Research Programs/Design
14.1.1.2 Market Size Estimation
14.1.1.3 Market Breakdown and Data Triangulation
14.1.2 Data Source
14.1.2.1 Secondary Sources
14.1.2.2 Primary Sources
14.2 Author Details
14.3 Disclaimer
FEATURED COMPANIES
Mitsubishi Tanabe Pharma
Sanofi
Mylan Pharma
Apotex
Glemark Generics
Covis Pharma
Sun Pharma
Lunan Pharma
List of Tables
 Table 1. Global Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size Growth Rate (CAGR) by Type (US$ Million): 2020 VS 2024 VS 2031
 Table 2. Global Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size Growth by Application (US$ Million): 2020 VS 2024 VS 2031
 Table 3. Global Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size by Region (US$ Million): 2024 VS 2031
 Table 4. Global Amyotrophic Lateral Sclerosis (ALS) Treatment Revenue by Region (2020-2025) & (US$ Million)
 Table 5. Global Amyotrophic Lateral Sclerosis (ALS) Treatment Revenue Forecast by Region (2026-2031) & (US$ Million)
 Table 6. Global Amyotrophic Lateral Sclerosis (ALS) Treatment Revenue by Type (2020-2025) & (US$ Million)
 Table 7. Global Amyotrophic Lateral Sclerosis (ALS) Treatment Revenue Forecast by Type (2026-2031) & (US$ Million)
 Table 8. Global Amyotrophic Lateral Sclerosis (ALS) Treatment Revenue by Application (2020-2025) & (US$ Million)
 Table 9. Global Amyotrophic Lateral Sclerosis (ALS) Treatment Revenue Forecast by Application (2026-2031) & (US$ Million)
 Table 10. Amyotrophic Lateral Sclerosis (ALS) Treatment Revenue by Company (2020-2025) & (US$ Million)
 Table 11. Amyotrophic Lateral Sclerosis (ALS) Treatment Revenue Share by Company (2020-2025)
 Table 12. Ranking of Global Top Amyotrophic Lateral Sclerosis (ALS) Treatment Players by Revenue (US$ Million) in 2024
 Table 13. Global Amyotrophic Lateral Sclerosis (ALS) Treatment Companies Market Concentration Ratio (CR5 and HHI) & (2020-2025)
 Table 14. Global Amyotrophic Lateral Sclerosis (ALS) Treatment by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Amyotrophic Lateral Sclerosis (ALS) Treatment as of 2024)
 Table 15. Global Amyotrophic Lateral Sclerosis (ALS) Treatment Companies Headquarters
 Table 16. Date of International Companies Enter into Amyotrophic Lateral Sclerosis (ALS) Treatment Market
 Table 17. Global Amyotrophic Lateral Sclerosis (ALS) Treatment Companies Product & Service
 Table 18. Global Amyotrophic Lateral Sclerosis (ALS) Treatment Mergers & Acquisitions, Expansion Plans
 Table 19. Mitsubishi Tanabe Pharma Corporation Information
 Table 20. Mitsubishi Tanabe Pharma Description and Business Overview
 Table 21. Mitsubishi Tanabe Pharma Amyotrophic Lateral Sclerosis (ALS) Treatment Product
 Table 22. Mitsubishi Tanabe Pharma Amyotrophic Lateral Sclerosis (ALS) Treatment Revenue (US$ Million) and Gross Margin (2020-2025)
 Table 23. Mitsubishi Tanabe Pharma Revenue Proportion of Amyotrophic Lateral Sclerosis (ALS) Treatment by Product in 2024
 Table 24. Mitsubishi Tanabe Pharma Revenue Proportion of Amyotrophic Lateral Sclerosis (ALS) Treatment by Application in 2024
 Table 25. Mitsubishi Tanabe Pharma Revenue Proportion of Amyotrophic Lateral Sclerosis (ALS) Treatment by Geographic Area in 2024
 Table 26. Mitsubishi Tanabe Pharma Recent Developments
 Table 27. Sanofi Corporation Information
 Table 28. Sanofi Description and Business Overview
 Table 29. Sanofi Amyotrophic Lateral Sclerosis (ALS) Treatment Product
 Table 30. Sanofi Amyotrophic Lateral Sclerosis (ALS) Treatment Revenue (US$ Million) and Gross Margin (2020-2025)
 Table 31. Sanofi Revenue Proportion of Amyotrophic Lateral Sclerosis (ALS) Treatment by Product in 2024
 Table 32. Sanofi Revenue Proportion of Amyotrophic Lateral Sclerosis (ALS) Treatment by Application in 2024
 Table 33. Sanofi Revenue Proportion of Amyotrophic Lateral Sclerosis (ALS) Treatment by Geographic Area in 2024
 Table 34. Sanofi Recent Developments
 Table 35. Mylan Pharma Corporation Information
 Table 36. Mylan Pharma Description and Business Overview
 Table 37. Mylan Pharma Amyotrophic Lateral Sclerosis (ALS) Treatment Product
 Table 38. Mylan Pharma Amyotrophic Lateral Sclerosis (ALS) Treatment Revenue (US$ Million) and Gross Margin (2020-2025)
 Table 39. Mylan Pharma Revenue Proportion of Amyotrophic Lateral Sclerosis (ALS) Treatment by Product in 2024
 Table 40. Mylan Pharma Revenue Proportion of Amyotrophic Lateral Sclerosis (ALS) Treatment by Application in 2024
 Table 41. Mylan Pharma Revenue Proportion of Amyotrophic Lateral Sclerosis (ALS) Treatment by Geographic Area in 2024
 Table 42. Mylan Pharma Recent Developments
 Table 43. Apotex Corporation Information
 Table 44. Apotex Description and Business Overview
 Table 45. Apotex Amyotrophic Lateral Sclerosis (ALS) Treatment Product
 Table 46. Apotex Amyotrophic Lateral Sclerosis (ALS) Treatment Revenue (US$ Million) and Gross Margin (2020-2025)
 Table 47. Apotex Revenue Proportion of Amyotrophic Lateral Sclerosis (ALS) Treatment by Product in 2024
 Table 48. Apotex Revenue Proportion of Amyotrophic Lateral Sclerosis (ALS) Treatment by Application in 2024
 Table 49. Apotex Revenue Proportion of Amyotrophic Lateral Sclerosis (ALS) Treatment by Geographic Area in 2024
 Table 50. Apotex Recent Developments
 Table 51. Glemark Generics Corporation Information
 Table 52. Glemark Generics Description and Business Overview
 Table 53. Glemark Generics Amyotrophic Lateral Sclerosis (ALS) Treatment Product
 Table 54. Glemark Generics Amyotrophic Lateral Sclerosis (ALS) Treatment Revenue (US$ Million) and Gross Margin (2020-2025)
 Table 55. Glemark Generics Revenue Proportion of Amyotrophic Lateral Sclerosis (ALS) Treatment by Product in 2024
 Table 56. Glemark Generics Revenue Proportion of Amyotrophic Lateral Sclerosis (ALS) Treatment by Application in 2024
 Table 57. Glemark Generics Revenue Proportion of Amyotrophic Lateral Sclerosis (ALS) Treatment by Geographic Area in 2024
 Table 58. Glemark Generics Recent Developments
 Table 59. Covis Pharma Corporation Information
 Table 60. Covis Pharma Description and Business Overview
 Table 61. Covis Pharma Amyotrophic Lateral Sclerosis (ALS) Treatment Product
 Table 62. Covis Pharma Amyotrophic Lateral Sclerosis (ALS) Treatment Revenue (US$ Million) and Gross Margin (2020-2025)
 Table 63. Covis Pharma Revenue Proportion of Amyotrophic Lateral Sclerosis (ALS) Treatment by Product in 2024
 Table 64. Covis Pharma Revenue Proportion of Amyotrophic Lateral Sclerosis (ALS) Treatment by Application in 2024
 Table 65. Covis Pharma Revenue Proportion of Amyotrophic Lateral Sclerosis (ALS) Treatment by Geographic Area in 2024
 Table 66. Covis Pharma Recent Developments
 Table 67. Sun Pharma Corporation Information
 Table 68. Sun Pharma Description and Business Overview
 Table 69. Sun Pharma Amyotrophic Lateral Sclerosis (ALS) Treatment Product
 Table 70. Sun Pharma Amyotrophic Lateral Sclerosis (ALS) Treatment Revenue (US$ Million) and Gross Margin (2020-2025)
 Table 71. Sun Pharma Revenue Proportion of Amyotrophic Lateral Sclerosis (ALS) Treatment by Product in 2024
 Table 72. Sun Pharma Revenue Proportion of Amyotrophic Lateral Sclerosis (ALS) Treatment by Application in 2024
 Table 73. Sun Pharma Revenue Proportion of Amyotrophic Lateral Sclerosis (ALS) Treatment by Geographic Area in 2024
 Table 74. Sun Pharma Recent Developments
 Table 75. Lunan Pharma Corporation Information
 Table 76. Lunan Pharma Description and Business Overview
 Table 77. Lunan Pharma Amyotrophic Lateral Sclerosis (ALS) Treatment Product
 Table 78. Lunan Pharma Amyotrophic Lateral Sclerosis (ALS) Treatment Revenue (US$ Million) and Gross Margin (2020-2025)
 Table 79. Lunan Pharma Revenue Proportion of Amyotrophic Lateral Sclerosis (ALS) Treatment by Product in 2024
 Table 80. Lunan Pharma Revenue Proportion of Amyotrophic Lateral Sclerosis (ALS) Treatment by Application in 2024
 Table 81. Lunan Pharma Revenue Proportion of Amyotrophic Lateral Sclerosis (ALS) Treatment by Geographic Area in 2024
 Table 82. Lunan Pharma Recent Developments
 Table 83. North America Amyotrophic Lateral Sclerosis (ALS) Treatment Revenue by Country (2020-2025) & (US$ Million)
 Table 84. North America Amyotrophic Lateral Sclerosis (ALS) Treatment Revenue by Country (2026-2031) & (US$ Million)
 Table 85. North America Amyotrophic Lateral Sclerosis (ALS) Treatment Revenue by Type (2020-2025) & (US$ Million)
 Table 86. North America Amyotrophic Lateral Sclerosis (ALS) Treatment Revenue by Application (2020-2025) & (US$ Million)
 Table 87. Asia-Pacific Amyotrophic Lateral Sclerosis (ALS) Treatment Revenue by Region (2020-2025) & (US$ Million)
 Table 88. Asia-Pacific Amyotrophic Lateral Sclerosis (ALS) Treatment Revenue by Region (2026-2031) & (US$ Million)
 Table 89. Asia-Pacific Amyotrophic Lateral Sclerosis (ALS) Treatment Revenue by Type (2020-2025) & (US$ Million)
 Table 90. Asia-Pacific Amyotrophic Lateral Sclerosis (ALS) Treatment Revenue by Application (2020-2025) & (US$ Million)
 Table 91. Europe Amyotrophic Lateral Sclerosis (ALS) Treatment Revenue by Country (2020-2025) & (US$ Million)
 Table 92. Europe Amyotrophic Lateral Sclerosis (ALS) Treatment Revenue by Country (2026-2031) & (US$ Million)
 Table 93. Europe Amyotrophic Lateral Sclerosis (ALS) Treatment Revenue by Type (2020-2025) & (US$ Million)
 Table 94. Europe Amyotrophic Lateral Sclerosis (ALS) Treatment Revenue by Application (2020-2025) & (US$ Million)
 Table 95. Latin America Amyotrophic Lateral Sclerosis (ALS) Treatment Revenue by Country (2020-2025) & (US$ Million)
 Table 96. Latin America Amyotrophic Lateral Sclerosis (ALS) Treatment Revenue by Country (2026-2031) & (US$ Million)
 Table 97. Latin America Amyotrophic Lateral Sclerosis (ALS) Treatment Revenue by Type (2020-2025) & (US$ Million)
 Table 98. Latin America Amyotrophic Lateral Sclerosis (ALS) Treatment Revenue by Application (2020-2025) & (US$ Million)
 Table 99. Middle East and Africa Amyotrophic Lateral Sclerosis (ALS) Treatment Revenue by Country (2020-2025) & (US$ Million)
 Table 100. Middle East and Africa Amyotrophic Lateral Sclerosis (ALS) Treatment Revenue by Country (2026-2031) & (US$ Million)
 Table 101. Middle East and Africa Amyotrophic Lateral Sclerosis (ALS) Treatment Revenue by Type (2020-2025) & (US$ Million)
 Table 102. Middle East and Africa Amyotrophic Lateral Sclerosis (ALS) Treatment Revenue by Application (2020-2025) & (US$ Million)
 Table 103. Amyotrophic Lateral Sclerosis (ALS) Treatment Key Raw Materials, Industry Status and Trend
 Table 104. Amyotrophic Lateral Sclerosis (ALS) Treatment Key Raw Materials and Upstream Suppliers
 Table 105. Amyotrophic Lateral Sclerosis (ALS) Treatment Clients Status and Trend
 Table 106. Amyotrophic Lateral Sclerosis (ALS) Treatment Typical Clients
 Table 107. Amyotrophic Lateral Sclerosis (ALS) Treatment Distributors
 Table 108. Amyotrophic Lateral Sclerosis (ALS) Treatment Market Trends
 Table 109. Amyotrophic Lateral Sclerosis (ALS) Treatment Market Drivers
 Table 110. Amyotrophic Lateral Sclerosis (ALS) Treatment Market Challenges
 Table 111. Amyotrophic Lateral Sclerosis (ALS) Treatment Market Restraints
 Table 112. Research Programs/Design for This Report
 Table 113. Key Data Information from Secondary Sources
 Table 114. Key Data Information from Primary Sources


List of Figures
 Figure 1. Amyotrophic Lateral Sclerosis (ALS) Treatment Product Picture
 Figure 2. Global Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size by Type (US$ Million): 2020 VS 2024 VS 2031
 Figure 3. Global Amyotrophic Lateral Sclerosis (ALS) Treatment Revenue Market Share by Type in 2024 & 2031
 Figure 4. Riluzole Product Picture
 Figure 5. Edaravone (Radicava) Product Picture
 Figure 6. Other Product Picture
 Figure 7. Global Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size by Application (US$ Million): 2020 VS 2024 VS 2031
 Figure 8. Global Amyotrophic Lateral Sclerosis (ALS) Treatment Revenue Market Share by Application in 2024 & 2031
 Figure 9. Hospital
 Figure 10. Drugs Store
 Figure 11. Other
 Figure 12. Amyotrophic Lateral Sclerosis (ALS) Treatment Report Years Considered
 Figure 13. Global Amyotrophic Lateral Sclerosis (ALS) Treatment Revenue, (US$ Million), 2020 VS 2024 VS 2031
 Figure 14. Global Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size (2020-2031) & (US$ Million)
 Figure 15. Global Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size Market Share by Region: 2024 Versus 2031
 Figure 16. Global Amyotrophic Lateral Sclerosis (ALS) Treatment Revenue Market Share by Region (2020-2031)
 Figure 17. Global Amyotrophic Lateral Sclerosis (ALS) Treatment Revenue Market Share Forecast by Type (2020-2031)
 Figure 18. Global Amyotrophic Lateral Sclerosis (ALS) Treatment Revenue Market Share Forecast by Application (2020-2031)
 Figure 19. Riluzole of Amyotrophic Lateral Sclerosis (ALS) Treatment Revenue Market Share by Application, 2024 VS 2031
 Figure 20. Edaravone (Radicava) of Amyotrophic Lateral Sclerosis (ALS) Treatment Revenue Market Share by Application, 2024 VS 2031
 Figure 21. Other of Amyotrophic Lateral Sclerosis (ALS) Treatment Revenue Market Share by Application, 2024 VS 2031
 Figure 22. Amyotrophic Lateral Sclerosis (ALS) Treatment Revenue Share by Company (2024)
 Figure 23. Amyotrophic Lateral Sclerosis (ALS) Treatment Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2020 VS 2024
 Figure 24. Riluzole Revenue Proportion by Company in 2024
 Figure 25. Edaravone (Radicava) Revenue Proportion by Company in 2024
 Figure 26. Other Revenue Proportion by Company in 2024
 Figure 27. North America Amyotrophic Lateral Sclerosis (ALS) Treatment Revenue 2020-2031 (US$ Million)
 Figure 28. North America Amyotrophic Lateral Sclerosis (ALS) Treatment Revenue Market Share by Type (2020-2025)
 Figure 29. North America Amyotrophic Lateral Sclerosis (ALS) Treatment Revenue Market Share by Application (2020-2025)
 Figure 30. Asia-Pacific Amyotrophic Lateral Sclerosis (ALS) Treatment Revenue 2020-2031 (US$ Million)
 Figure 31. Asia-Pacific Amyotrophic Lateral Sclerosis (ALS) Treatment Revenue Market Share by Region (2020-2031)
 Figure 32. Asia-Pacific Amyotrophic Lateral Sclerosis (ALS) Treatment Revenue Market Share by Type (2020-2025)
 Figure 33. Asia-Pacific Amyotrophic Lateral Sclerosis (ALS) Treatment Revenue Market Share by Application (2020-2025)
 Figure 34. Europe Amyotrophic Lateral Sclerosis (ALS) Treatment Revenue Growth Rate 2020-2031 (US$ Million)
 Figure 35. Europe Amyotrophic Lateral Sclerosis (ALS) Treatment Revenue Market Share by Country (2020-2031)
 Figure 36. Europe Amyotrophic Lateral Sclerosis (ALS) Treatment Revenue Market Share by Type (2020-2025)
 Figure 37. Europe Amyotrophic Lateral Sclerosis (ALS) Treatment Revenue Market Share by Application (2020-2025)
 Figure 38. Latin America Amyotrophic Lateral Sclerosis (ALS) Treatment Revenue Growth Rate 2020-2031 (US$ Million)
 Figure 39. Latin America Amyotrophic Lateral Sclerosis (ALS) Treatment Revenue Market Share by Country (2020-2031)
 Figure 40. Latin America Amyotrophic Lateral Sclerosis (ALS) Treatment Revenue Market Share by Type (2020-2025)
 Figure 41. Latin America Amyotrophic Lateral Sclerosis (ALS) Treatment Revenue Market Share by Application (2020-2025)
 Figure 42. Middle East and Africa Amyotrophic Lateral Sclerosis (ALS) Treatment Revenue Growth Rate 2020-2031 (US$ Million)
 Figure 43. Middle East and Africa Amyotrophic Lateral Sclerosis (ALS) Treatment Revenue Market Share by Country (2020-2031)
 Figure 44. Middle East and Africa Amyotrophic Lateral Sclerosis (ALS) Treatment Revenue Market Share by Type (2020-2025)
 Figure 45. Middle East and Africa Amyotrophic Lateral Sclerosis (ALS) Treatment Revenue Market Share by Application (2020-2025)
 Figure 46. Amyotrophic Lateral Sclerosis (ALS) Treatment Supply Chain (Upstream and Downstream Market)
 Figure 47. Global Production Market Share of Amyotrophic Lateral Sclerosis (ALS) Treatment Raw Materials by Region in 2024
 Figure 48. Amyotrophic Lateral Sclerosis (ALS) Treatment Distribution Channels
 Figure 49. Global Amyotrophic Lateral Sclerosis (ALS) Treatment Percentage 2020-2031: Indirect Sales VS Direct Sales
 Figure 50. Global Amyotrophic Lateral Sclerosis (ALS) Treatment Percentage 2020-2031: Online Sales VS Offline Sales
 Figure 51. Bottom-up and Top-down Approaches for This Report
 Figure 52. Data Triangulation
 Figure 53. Key Executives Interviewed
SELECT A FORMAT
Added to Cart
Electronic (PDF)

$5900

This license allows only one user to access the PDF.
Electronic (PDF)

$8850

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together
Electronic (PDF)

$11800

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report
Add to Cart
Buy Now (15% Discount)
INQUIRE FOR DISCOUNT

HAVE A QUERY?

INQUIRE ABOUT REPORT EMAIL US

OUR CUSTOMER

Novocure

SIMILAR REPORTS

Global Amyotrophic Lateral Sclerosis ALS Market Insights Forecast to 2030
Global Amyotrophic Lateral Sclerosis Therapeutics Market Insights Forecast to 2030
Global Amyotrophic Lateral Sclerosis ALS Devices Market Research Report 2024
Rare Neurodegenerative Disease Treatment Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Spinal Muscular Atrophy Treatment Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global Neurodegenerative Disease Market Insights Forecast to 2030
Global Spinal Muscular Atrophy SMA Treatment Market Research Report 2024
Global Amyotrophic Lateral Sclerosis Device Market Research Report 2025
Global Parkinson s Disease Treatment Market Insights Forecast to 2030
Global Alzheimer s Disease Treatments Market Research Report 2024
Global Neurodegenerative Disease Treatment Market Research Report 2024
Global Alzheimer s Disease Drug Market Insights Forecast to 2030
Global Alzheimer Treatment Drug Market Research Report 2025
Alzheimer Disease Genetic Testing Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global Rilutek Market Insights Forecast to 2030
Global Neurologic Disorders Therapeutics Market Insights Forecast to 2030
Global TIGLUTIK Market Insights Forecast to 2030
Global Alzheimer s Disease Therapeutics and Diagnostics Market Insights Forecast to 2030
Global Teglutik Market Insights Forecast to 2030
Global Gene Therapy for Inherited Genetic Disorders Market Insights Forecast to 2030

RELATED REPORTS

Global Attention Deficit Hyperactivity Disorder (ADHD) Drugs Market Research Report 2025

120 Pages
Type: Report
Code: QYRE-Auto-13Z8760
Tue Sep 09 00:00:00 UTC 2025

Add to Cart

Global Intracranial Pressure (ICP) Monitoring Market Research Report 2025

120 Pages
Type: Report
Code: QYRE-Auto-37L4006
Mon Sep 08 00:00:00 UTC 2025

Add to Cart

Global Brain Disease Market Research Report 2025

120 Pages
Type: Report
Code: QYRE-Auto-12P6151
Mon Sep 08 00:00:00 UTC 2025

Add to Cart

Global Amyotrophic Lateral Sclerosis (Lou Gehrig’s Disease) Treatment Market Research Report 2025

120 Pages
Type: Report
Code: QYRE-Auto-3X6389
Mon Sep 08 00:00:00 UTC 2025

Add to Cart

Call
Buy Now
REQUEST FREE SAMPLE REPORT
Support Contacts
U.S. (TOLL FREE)
+1 (425) 388-2538
THE COMPANY
OUR PRODUCTS
CUSTOMER SUPPORT
POLICES
THE COMPANY
CUSTOMER SUPPORT
OUR PRODUCTS
POLICES
Copyright © 2018 Valuates.com. All Rights Reserved.
Sitemap - Privacy Policy - Terms & Conditions